TMCnet News
Roger Longman and Ed Saltzman to Debate Solutions for Embattled Pharma and Biotech Industries During Featured Session, Moderated by David Flores, at Upcoming LES (USA & Canada) Annual Meeting in San DiegoSAN DIEGO --(Business Wire)-- Tough economic times have put big pharma and biotechs on the critical list. Shrinking budgets, drug pipelines, R&D and venture money are just a few of the hurdles facing the life science industry. Can it be revived? Roger Longman and Ed Saltzman will debate possible solutions during a featured plenary session, moderated by David Flores, at the 2011 Licensing Executives Society (U.S.A. and Canada) Inc., Annual Meeting, October 16-19, in San Diego (www.les2011.org). "Is pharma ready to revive itself in the post-patent cliff world? Can biotech find a way to finance its innovations through to successful exits when regulatory and payer risk and pharma's business-development trepidation are at all-time highs? The answers are yes -- though the solutions are radical," said panel moderator David Flores, Co-Founder, President and CEO, BioCentury Publications, Inc. "Better engines of value creation can be developed, but only if truly fresh thinking replaces orthodoxies about business models, partnerships and intellectual property." Mr. Flores will be joined for the paneltitled "Can Biopharma Still Create Value…And How?" by Ed Saltzman, President of Defined Health, and Roger Longman, Chief Executive Officer of Real Endpoints LLC (formerly Managing Director, Windhover Information), who will share insights about how companies have dealt with obstacles that are plaguing the industry. Their case studies will illustrate the potential for success amid the difficulties posed by today's tumultuous economic environment. Over 1,000 IP, licensing and business development professionals from companies, research institutions, government labs and other technology-oriented organizations are expected to attend the LES Annual Meeting, which will offer an impressive line-up of senior experts, who will share tools and strategies for creating opportunities during myriad of industry-specific plenary, mini-plenary and small-group workshops. LES recently announced the addition of plenary speakers Barbara Dalton, Vice President of Venture Capital at Pfizer, and Martha Reis, Vice President of Intellectual Property Management at The Boeing (News - Alert) Company. They join top-tier executive presenters John Milligan, CEO, Gilead; George Golumbeski, Senior VP of Business Development, Celgene Corporation; and Mark Noguchi, Global Head of Strategic Alliance Management & Partnering, Roche, on the meeting program. "This is the premier IP and licensing meeting of the year," said LES President Michael Lasinski (News - Alert). "The program is interactive, diverse and relevant to all sectors of the licensing, business development and legal communities. Attendees will walk away with connections, information and education that simply can't be matched by any other event." Other meeting highlights for life sciences professionals include:
Registrants can save $100 off meeting registration by visiting www.les2011.org and registering before August 31st!
|
